Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

If a company files for Chapter 7 bankruptcy, that means it's heading for liquidation, in which assets are sold off to pay creditors.

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

BofA cuts Pfizer’s Q1 2025 EPS estimate by 4.9% and revenue by 2.1% due to updated assumptions. Pfizer stock trades at 7x expected 2024 earnings, lower than peer average; dividend yield stands ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors ...

Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The company’s fifty day moving average price is $28.43 and its 200 day moving average price is $38.46.

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29.